Advanced Lung Cancer That's No Longer Responding to Treatment?
For advanced NSCLC that has progressed after targeted therapy, chemotherapy, or immunotherapy, GC101 TIL therapy offers a new option with 41.7% response rates and only mild conditioning.
Lung Cancer in Context
Lung cancer is the most common cancer worldwide and the leading cause of cancer-related death. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. While significant progress has been made with targeted therapies and immunotherapies, most patients eventually develop resistance and disease progression.
For patients who have failed first-line chemotherapy and second-line immunotherapy, treatment options become very limited. GC101 TIL therapy is being studied as a potential third-line or later option for advanced NSCLC patients who have exhausted standard treatments.
GC101 Clinical Results for Lung Cancer
The GC101 clinical program for NSCLC includes a completed Phase I trial and the ongoing MIZAR-005 Phase Ib/II trial, led by Prof. Shun Lu (陆舜) at Shanghai Chest Hospital.
Phase I Results
In the completed Phase I dose-escalation study across multiple solid tumors including NSCLC, GC101 demonstrated a 41.7% objective response rate in evaluable NSCLC patients. One patient with advanced NSCLC achieved a complete response (CR) — all detectable tumor disappeared and the patient remained disease-free at last follow-up. The disease control rate (DCR) in NSCLC patients was approximately 75%.
MIZAR-005: Phase Ib/II Trial — Now Enrolling
The MIZAR-005 trial (NCT06473961) is an open-label, multicenter Phase Ib/II study designed to evaluate the safety and efficacy of GC101 in patients with advanced NSCLC who have progressed on or after platinum-based chemotherapy and anti-PD-1 immunotherapy. The trial is led by Prof. Shun Lu (陆舜) at Shanghai Chest Hospital and is currently activating recruitment.
Trial ID: NCT06473961 | Phase: Ib/II | Indication: Advanced NSCLC | PI: Shun Lu, Shanghai Chest Hospital | Status: Activating — accepting eligibility enquiries
How TIL Therapy Works for Lung Cancer
The treatment process for lung cancer patients follows the same general TIL therapy pathway, with specific considerations for thoracic tumors:
- Tumor tissue collection: A sample of the lung tumor is obtained, typically through a minimally invasive biopsy or during a planned surgical procedure.
- TIL isolation and expansion: The TILs are extracted from the tumor tissue and expanded using Juncell's DeepTIL platform over approximately 4–6 weeks.
- Pre-infusion preparation: Unlike conventional TIL therapy, GC101 does not require lymphodepletion chemotherapy, significantly reducing the toxicity burden.
- Cell infusion: The expanded TILs are infused intravenously in a hospital setting over approximately 30–60 minutes.
- Monitoring: Post-infusion monitoring for 3–7 days to manage any immune-related reactions.
Eligibility Criteria
- Diagnosis: Histologically confirmed advanced NSCLC (squamous or non-squamous)
- Prior treatment: Progression after platinum-based chemotherapy and anti-PD-1/PD-L1 therapy
- Measurable disease: At least one tumor lesion amenable to biopsy or surgical resection for TIL generation
- ECOG: Performance status 0–1
- Organ function: Adequate bone marrow, hepatic, and renal function
Safety Profile in Lung Cancer Patients
GC101's safety advantage is particularly relevant for lung cancer patients, who often have compromised pulmonary function. Without the need for lymphodepletion chemotherapy or high-dose IL-2, patients avoid the severe toxicities of conventional TIL therapy — febrile neutropenia, infections, respiratory compromise, and cardiac stress. The most common adverse events are mild to moderate: fever, chills, transient rash, and fatigue, all of which are manageable with standard supportive care.
Frequently Asked Questions
Is TIL therapy FDA-approved for lung cancer?
No. TIL therapy is not yet approved by any regulatory authority for lung cancer. The only FDA-approved TIL therapy (Iovance's Amtagvi/lifileucel) is approved for melanoma only. GC101 is an investigational therapy being studied in clinical trials in China.
How does GC101 compare to CAR-T therapy?
While both are cell therapies, they work very differently. CAR-T therapy is approved for blood cancers (leukemia, lymphoma) but has limited efficacy in solid tumors. TIL therapy, by contrast, is specifically designed for solid tumors. GC101 uses the patient's own naturally occurring tumor-targeting T cells rather than genetically engineered cells, and is better suited for solid tumor microenvironments.
How is GC101 different from other TIL therapies?
GC101 is the world's first TIL therapy that does not require lymphodepletion chemotherapy or IL-2 injections. This is made possible by Juncell's DeepTIL platform, which selects TIL populations with superior properties, enabling a safer treatment that can be administered in a general ward.
What are the side effects for lung cancer patients?
The most common side effects are immune-related: fever, chills, fatigue, and rash. These are manageable with standard medications. Unlike conventional TIL therapy, GC101 avoids the severe toxicities from lymphodepletion (infections, organ toxicity) and high-dose IL-2 (flu-like symptoms, fluid retention, cardiac stress).
Who leads the NSCLC trial?
The MIZAR-005 trial is led by Prof. Shun Lu (陆舜) at Shanghai Chest Hospital. Prof. Lu is one of China's leading thoracic oncologists and has published extensively on lung cancer immunotherapy and targeted therapy.
Frequently Asked Questions About TIL Therapy for Lung Cancer
How effective is TIL therapy for advanced lung cancer?
Phase Ib data from the MIZAR-005 predecessor trial shows 41.7% objective response rate and 66.7% 12-month overall survival in advanced NSCLC patients with a median of 3 prior treatment lines. These results compare favorably to standard third-line treatment options.
What is the MIZAR-005 trial?
MIZAR-005 (NCT06473961) is an open Phase Ib/II clinical trial of GC101 TIL therapy in advanced NSCLC patients who have failed targeted therapy plus platinum chemotherapy, or PD-(L)1 inhibitor plus platinum chemotherapy. The trial is led by Prof. Shun Lu at Shanghai Chest Hospital.
How does TIL therapy differ from CAR-T for solid tumors?
TIL therapy uses your body's own tumor-resident immune cells — no genetic engineering required. Unlike CAR-T which targets a single antigen, TILs naturally recognize multiple tumor targets simultaneously, reducing the chance of immune escape.
Can international patients enroll in the NSCLC trial?
Yes. Foreign nationals can legally participate in Chinese clinical trials. The coordinating team at Juncell works in English. You'll need to submit medical records for review, and be willing to travel to Shanghai for biopsy and Hainan for infusion.
What is the expected timeline for treatment?
Free consultation → eligibility review (1-2 weeks) → biopsy in Shanghai (3-5 days) → cell manufacturing at home (4-6 weeks) → infusion in Hainan (2-3 weeks) → remote follow-up. Most patients can complete the process within 3-4 months.
Explore TIL Therapy for Lung Cancer
If you or a loved one has advanced NSCLC that has progressed after standard treatments, GC101 TIL therapy may offer a new option.
Email clinicaltrials@juncell.com →